Substandard and Falsified Medical Products, Devices, and Online Pharmacy Supply-Chain Security: Scoping Review with ☸️SAIMSARA.

Name: SAIMSARA Evidence Object longevity::FALSIFIED_MEDICAL_PRODUCTS_SS
Creator: SAIMSARA
License: https://saimsara.com/license/

SAIMSARA

doi:10.62487/saimsarab2913b49

SAIMSARA Journal

Machine-Readable Science • ISSN 3054-3991

Substandard and Falsified Medical Products, Devices, and Online Pharmacy Supply-Chain Security: Scoping Review with ☸️SAIMSARA.

Longevity & Public Health

Issue 2, Volume 1, 2026

Chat with this issue

DOI: 10.62487/saimsarab2913b49

Editorial note

• Last update: 2026-05-27 21:53:37

What is this paper about

Falsified medical products are not a niche drug-safety problem, but a supply-chain failure spanning medicines, devices, online pharmacies, informal markets, and weak regulatory systems. The full evidence map shows where risk concentrates — from semaglutide and PDE-5 products to vaccines, antibiotics, devices, and digital marketplaces — and which detection, reporting, and regulatory tools can realistically close the gaps.

Human-verified editorial review Verified by World ID proof-of-human. This editorial layer was submitted from a SAIMSARA account verified as a unique human.

Abstract: To map and synthesize original research on falsified medical products, focusing on where they are detected, which product categories and distribution channels are implicated, how they are identified, and what system-level responses are supported by the evidence. The review uses 96 references and builds its evidence map from 71 original studies with 99925 total participants/sample observations (topic-deduplicated ΣN). Across regulatory, laboratory, online, and frontline settings, the evidence suggests that falsified medical products are best understood as a systems-level supply-chain and market-integrity problem rather than a discrete therapeutic-class issue, consistently co-occurring with substandard quality where oversight, affordability, and authentication infrastructure are weakest. Routine multi-country surveillance indicated low but persistent background signals, such as 1.8% probably falsified samples across 13 low- and middle-income countries, whereas targeted online channels showed concentrated risk, including all six illegal online semaglutide products classified as substandard and falsified. Pharmacovigilance signals across 6,302 counterfeit-medicine adverse-event reports further highlight lifestyle, sexual health, and antiviral products as recurrent concerns. These patterns support pairing field-deployable screening and digital reporting with regulatory maturity and equitable access measures. Future research should prioritize harmonized, denominator-based surveillance of online and informal channels linking product testing to patient exposure and enforcement outcomes.

Keywords: Falsified medical products; Substandard medicines; Counterfeit medicines; Medicine quality; Pharmacovigilance; Post-marketing surveillance; Online pharmacies; Regulatory oversight; Supply chain security; Analytical detection

Review Stats

Final search date and database lock: 2026-05-19 20:05:54 CEST
Plan: Pro (expanded craft tokens; source: Semantic Scholar)
Source: Semantic Scholar
Total Abstracts/Papers: 130060
Downloaded Abstracts/Papers: 1000
Included original and non-original Abstracts/Papers (all): 137
Included original Abstracts/Papers (Vote counting by direction of effect): 71
Reference Index (links used in paper): 96
Total participants/sample observations (topic deduplicated ΣN): 99925

Get access to the full paper

Unlock the full evidence map

Full paper access includes the complete human-readable review, figures, reference index, PDF export, and machine-readable Evidence JSON download.
Evidence JSON can also be purchased separately if you only need the LLM-ready object for agent, AI, or RAG workflows.
Institutional or library access? Sign in with your institution email to open all available SAIMSARA papers under your institution access arrangement.
Need a SAIMSARA review on your own topic? ☸️Request.

Reference Index (96)

[1] Substandard and falsified medical product recalls in Zambia from 2018 to 2021 and implications on the quality surveillance systems — https://doi.org/10.1177/27550834221141767
[2] Analysis of pharmacovigilance databases for spontaneous reports of adverse drug reactions related to substandard and falsified medical products: A descriptive study — https://doi.org/10.3389/fphar.2022.964399
[3] Adoption of Falsified Medical Products in a Low-Income Country: Empirical Evidence for Suriname — https://doi.org/10.3390/su9101732
[4] Biochemical profiling provides a low-cost and globally accessible method to detect falsified vaccines and insulin — https://doi.org/10.1038/s41598-026-37281-9
[5] Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study — https://doi.org/10.2196/65440
[6] Benchtop NMR spectroscopy in the analysis of substandard and falsified medicines as well as illegal drugs. — https://doi.org/10.1016/j.jpba.2019.112939
[7] Impact of the COVID-19 pandemic on the quality of medical products in Zimbabwe: a qualitative study based on key informant interviews with health system stakeholders — https://doi.org/10.1136/bmjopen-2022-068923
[8] A counterfeit multivitamin product inducing severe bleeding disorders in humans — https://doi.org/10.1080/15563650.2019.1703999

Unlock the full paper to view the complete Reference Index.